10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2013 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 21, 2014) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 2,576 | 5,963 | 4,728 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 928 | 1,363 | 1,395 |
| Amortization of intangible assets | 791 | 1,419 | 1,649 |
| Share-based compensation | 262 | 433 | 383 |
| Acquired in-process and collaborations research and development | 288 | 672 | |
| Investing and financing (gains) losses, net | 4 | 356 | 142 |
| Net loss on extinguishment of debt | 1,351 | ||
| Trade receivables | (113) | 36 | (670) |
| Inventories | (154) | (417) | (130) |
| Prepaid expenses and other assets | 131 | (35) | 413 |
| Trade accounts payable and other liabilities | (436) | (134) | 1,790 |
| Income taxes | (665) | (1,309) | (1,402) |
| Net Cash From Operating Activities | 3,324 | 9,314 | 8,970 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,145) | (1,795) | (1,491) |
| Acquisitions of businesses and technologies, net of cash acquired | (580) | (706) | (273) |
| Purchases of investment securities | (10,064) | (11,998) | (5,110) |
| Proceeds from sales of investment securities | 7,839 | 8,936 | 5,649 |
| Release of restricted funds | 1,870 | ||
| Other | 21 | 3 | 16 |
| Net Cash (Used in) From Investing Activities | (3,929) | (5,560) | 661 |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 2,086 | 784 | (1,965) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 9 | 14,700 | 1,000 |
| Repayments of long-term debt and debt with maturities over 3 months | (303) | (11,071) | (3,012) |
| Acquisition and contingent consideration payments related to business acquisitions | (495) | (521) | (400) |
| Transfer of cash and cash equivalents to AbbVie Inc. | (5,901) | ||
| Purchases of common shares | (1,605) | (2,364) | (77) |
| Proceeds from stock options exercised, including income tax benefit | 395 | 1,850 | 969 |
| Dividends paid | (882) | (3,183) | (2,938) |
| Net Cash (Used in) From Financing Activities | (6,696) | 195 | (6,423) |
| Effect of exchange rate changes on cash and cash equivalents | (26) | 40 | (43) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (7,327) | 3,989 | 3,165 |
| Cash and Cash Equivalents, Beginning of Year | 10,802 | 6,813 | |
| Cash and Cash Equivalents, End of Year | 3,475 | 10,802 | 6,813 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,039 | 1,367 | 1,782 |
| Interest paid | 148 | 576 | 545 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |